Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Kanion Pharmaceutical Co.,Ltd. (600557.SS)
CNY13.28
+0.32 (+2.47%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 58 Kangyuan Road 222000
Lianyungang, CN
Lianyungang, CN
CEO
Yongchun Yang
Website
kanion.com
IPO
2002-09-18
ISIN CNE000001CL7
Description
Jiangsu Kanion Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise focused on the research, development, production, and distribution of traditional Chinese medicines. The company's diverse product range targets several therapeutic areas, such as women's health, bone and joint conditions, antiviral treatments, and cardiovascular and cerebrovascular ailments. Founded in 1975, its primary operations are based in Lianyungang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY13.28
+0.32 (+2.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.45
Float Shares
337.83M
Free Float %
59.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.06% | +5.99% | -4.23% | -10.60% | -14.39% | -8.50% | -2.64% | -55.62% | +18.33% | -8.50% | +489.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
13.28
DCF (Unlevered)
8.13
-38.8%
DCF (Levered)
14.49
+9.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.18
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-16.2% Q1'26: -5.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-20.6% Q1'26: -6.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.1% Q1'26: -14.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.6% Q1'26: +12.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.6% ★ Q1'26: +10.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.8% ★ Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.91× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.82B
est: 2.88B (-2.0%)
|
3.00B
est: 3.02B (-0.7%)
|
3.27B
est: 3.29B (-0.4%)
|
3.82B
est: 3.58B (+7.0%)
|
4.57B
est: 4.61B (-1.0%)
|
3.03B
est: 3.75B (-19.1%)
|
3.65B
est: 3.71B (-1.7%)
|
4.35B
est: 4.46B (-2.5%)
|
4.86B
est: 4.57B (+6.3%)
|
3.90B
est: 3.90B (0.0%)
|
3.27B
est: 3.90B (-16.2%)
|
3.51B
3.51B – 3.51B
-10.0% YoY
|
3.73B
3.73B – 3.73B
+6.2% YoY
|
3.90B
3.90B – 3.90B
+4.8% YoY
|
| EBITDA |
572.86M
est: 401.86M (+42.6%)
|
612.02M
est: 422.28M (+44.9%)
|
640.85M
est: 459.25M (+39.5%)
|
689.68M
est: 499.52M (+38.1%)
|
780.68M
est: 644.40M (+21.1%)
|
477.89M
est: 523.40M (-8.7%)
|
527.06M
est: 518.57M (+1.6%)
|
638.01M
est: 623.60M (+2.3%)
|
644.32M
est: 654.80M (-1.6%)
|
604.27M
est: 557.98M (+8.3%)
|
447.85M
est: 557.98M (-19.7%)
|
502.15M
502.15M – 502.15M
-10.0% YoY
|
533.36M
533.36M – 533.36M
+6.2% YoY
|
558.84M
558.84M – 558.84M
+4.8% YoY
|
| EBIT |
465.55M
est: 264.95M (+75.7%)
|
473.19M
est: 278.42M (+70.0%)
|
490.37M
est: 302.79M (+61.9%)
|
526.68M
est: 329.34M (+59.9%)
|
614.76M
est: 424.86M (+44.7%)
|
318.31M
est: 345.09M (-7.8%)
|
340.05M
est: 341.90M (-0.5%)
|
448.18M
est: 411.15M (+9.0%)
|
449.45M
est: 429.59M (+4.6%)
|
407.90M
est: 366.06M (+11.4%)
|
249.16M
est: 366.06M (-31.9%)
|
329.44M
329.44M – 329.44M
-10.0% YoY
|
349.91M
349.91M – 349.91M
+6.2% YoY
|
366.63M
366.63M – 366.63M
+4.8% YoY
|
| Net Income |
362.34M
est: 372.63M (-2.8%)
|
373.74M
est: 358.49M (+4.3%)
|
373.78M
est: 367.77M (+1.6%)
|
414.05M
est: 351.74M (+17.7%)
|
506.99M
est: 484.07M (+4.7%)
|
262.92M
est: 293.90M (-10.5%)
|
320.54M
est: 351.52M (-8.8%)
|
434.47M
est: 410.30M (+5.9%)
|
464.16M
est: 520.77M (-10.9%)
|
391.86M
est: 387.82M (+1.0%)
|
303.93M
est: 401.97M (-24.4%)
|
351.02M
351.02M – 351.02M
-12.7% YoY
|
401.97M
401.97M – 401.97M
+14.5% YoY
|
458.59M
458.59M – 458.59M
+14.1% YoY
|
| SGA |
1.60B
est: 1.37B (+17.0%)
|
1.75B
est: 1.44B (+21.6%)
|
1.70B
est: 1.56B (+8.8%)
|
2.05B
est: 1.70B (+20.4%)
|
2.46B
est: 2.19B (+12.2%)
|
1.46B
est: 1.78B (-18.3%)
|
1.75B
est: 1.76B (-1.1%)
|
2.06B
est: 2.12B (-3.0%)
|
2.29B
est: 2.02B (+13.4%)
|
1.85B
est: 1.72B (+7.9%)
|
1.00B
est: 1.72B (-41.6%)
|
1.55B
1.55B – 1.55B
-10.0% YoY
|
1.64B
1.64B – 1.64B
+6.2% YoY
|
1.72B
1.72B – 1.72B
+4.8% YoY
|
| EPS |
0.59
est: 0.65 (-8.8%)
|
0.61
est: 0.62 (-1.9%)
|
0.63
est: 0.64 (-1.3%)
|
0.70
est: 0.61 (+14.7%)
|
0.86
est: 0.84 (+2.4%)
|
0.44
est: 0.51 (-13.7%)
|
0.56
est: 0.61 (-8.2%)
|
0.75
est: 0.71 (+5.3%)
|
0.81
est: 0.92 (-11.9%)
|
0.68
est: 0.69 (-0.7%)
|
0.54
est: 0.71 (-23.9%)
|
0.62
0.62 – 0.62
-12.7% YoY
|
0.71
0.71 – 0.71
+14.5% YoY
|
0.81
0.81 – 0.81
+14.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-706.93M
OE per share TTM
-1.24
Owner's Yield
-9.67%
Maintenance CapEx ratio
75.73%
Maint CapEx / Avg PPE
66.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 69.4K | 0.46% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 264.3K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 147.6K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 107.0K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 23.2K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.3K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.15M | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 70.1K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.3K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 980.3K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
45.8K
Shares Outstanding
566.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chuanlei Wang | Deputy General Manager | — | male |
| Feipeng Xian | Deputy General Manager | — | male |
| Jie Wang Tuan | Deputy General Manager | — | male |
| Li Qing | Accounting Supervisor | — | — |
| Pan Peng | Secretary | — | male |
| Quan Liu | Deputy General Manager | — | male |
| Suocheng Jiang | Chief Financial Officer & Director | — | male |
| Xiaoliang Zhang | Deputy General Manager | — | — |
| Yong Chun Yang | GM & Director | — | male |
| Yu Pan | Deputy GM & Market Development Center | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600557.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
